Please note: B-SMART concluded its activities in June 2022.
Innovative nanotechnological RNA delivery systems targeting the direct cause of Alzheimer‘s disease instead of its symptoms
Neurodegenerative diseases such as Alzheimer’s affect over 7 million people in Europe. Despite this fact, few treatments for this group of diseases are available so far. Nanomedical approaches can make a difference, providing new therapeutic options by helping drugs to enter the brain.
Therefore, the multinational research project B-SMART sets out to provide an RNA-based therapy perspective for neurodegenerative diseases targeting the direct cause of the disease instead of its symptoms in the midterm.
News & Events
-
B-SMART on the Homestretch: New Video Clip Highlights Project’s Pathway to Success
Over the past 5.5 years, the partners of the EU-funded research project B-SMART have been on a...Read more
"Transferring RNA therapeutics to the brain crossing the blood-cerebrospinal fluid barrier is a unique research endeavor. Finding a novel gateway to transport RNA to the brain will enable the development of causal therapies not only for Alzheimer’s, but for other diseases as well."
![Prof. Raymond Schiffelers Photo of Prof. Raymond Schiffelers](https://b-smart-project.eu/fileadmin/b-smart/images/rms.jpg)
Lack of causal therapies and effective drugs
RNA-based nanomedicines directly targeting the brain
Secure in-vivo transport through nanocarriers
Crossing the blood-cerebrospinal fluid barrier through ligands
Basis technology for treatment of other diseases